Webinar: Is America’s Future Obesity Free? (6/17/21)

Panelists: + Chantell Sell, PharmD, National Pharmacy Clinical Lead, Willis Towers Watson + Sami Inkinen, MSc, MBA, CEO as well as Co-Founder, Virta Health + Hassan Azar, JD, MBA, MPH, MHA, MA, VP Global Benefits, Jones Lang LaSalle Weight problems rates remain to skyrocket, yet earlier this month we were consulted with appealing information. On June 4th, the FDA approved a new weight-loss drug in which the outcomes which were referred to as "advancement" as well as "game-changing" Patients usually shed 33.7 pounds after 68 weeks, greater than 1.5 x greater than the following finest obesity medication. Specialists forecast the record-breaking efficiency prices might unleash the obesity drug market, which has historically stuck around at a reduced of much less than 1% penetration price. In spite of what resemble a promising turn of occasions at the surface area, there is expanding concern that we're at an oblique factor for a health care expense situation. With an estimated list price per person of $15,600 this newly approved GLP-1 might take a huge hit on payers and also employers who are currently battling to regulate growing medicine and healthcare costs. Find out more concerning Virta Health at https://www.virtahealth.com Follow us at: https://www.facebook.com/virtahealth/ https://www.linkedin.com/company/virta-health/

Leave a Reply

Your email address will not be published.